- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/58 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
Patent holdings for IPC class C07D 215/58
Total number of patents in this class: 92
10-year publication summary
6
|
8
|
9
|
6
|
8
|
7
|
7
|
8
|
3
|
0
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Zydus Lifesciences Limited | 103 |
10 |
Stemsynergy Therapeutics, Inc. | 18 |
6 |
Bristol-myers Squibb Company | 4865 |
4 |
The Regents of the University of Michigan | 4589 |
4 |
Merck Sharp & Dohme LLC | 3752 |
4 |
Cadila Healthcare Limited | 323 |
3 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 674 |
3 |
Lycera Corporation | 31 |
3 |
F. Hoffmann-La Roche AG | 7951 |
2 |
Pfizer Inc. | 3363 |
2 |
Korea Research Institute of Chemical Technology | 1340 |
2 |
National Cancer Center | 306 |
2 |
Ono Pharmaceutical Co., Ltd. | 436 |
2 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 806 |
2 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2842 |
2 |
Versitech Limited | 368 |
2 |
Nanjing Gear Pharma & Tech Co., Ltd. | 3 |
2 |
The Regents of the University of California | 19544 |
1 |
Merck Patent GmbH | 5848 |
1 |
FUJIFILM Corporation | 28829 |
1 |
Other owners | 34 |